Hickey M, Moss KM, Krejany EO, et al. - Researchers aimed at determining menopausal symptoms and quality of life up to 12 months after risk-reducing salpingo-oophorectomy (RRSO). In addition, they determined the effects of hormone therapy. They conducted a prospective observational study including 95 premenopausal women planning RRSO and a comparison group of 99 who retained their ovaries. Findings revealed an increase in vasomotor symptoms by 3 months following premenopausal RRSO; hot flush prevalence increased from 5.3% to 56.2% and night sweats from 20.2% to 47.2%. These symptoms persisted but did not worsen by 12 months. These vasomotor symptoms were described as “mild” by almost all women. Vasomotor symptoms were lowered by the hormone therapy but these did not resolve after RRSO. Hormone therapy led to an improvement in menopause related quality of life but not to pre-RRSO levels.